• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Shugan Jieyu capsule (舒肝解郁膠囊) improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized,double-blind,placebo-controlled trial

    2022-11-16 01:54:34ANXuedongZHANGQingTAOJunxiuLILiCHENYunLIKejianHEJingLIURuGUOJuanZHANGJiaZHUHuiLIANFengmeiLIXiaodong
    關(guān)鍵詞:膠囊

    AN Xuedong,ZHANG Qing,TAO Junxiu,LI Li,CHEN Yun,LI Kejian,HE Jing,LIU Ru,GUO Juan,ZHANG Jia,ZHU Hui,LIAN Fengmei,LI Xiaodong

    AN Xuedong,LIAN Fengmei,Endocrinology,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Beijing 100053,China

    ZHANG Qing,Orthopedics,Hubei Provincial Hospital of Traditional Chinese Medicine,Affiliated Hospital of Hubei University of Chinese Medicine,Hubei Institute of Traditional Chinese Medicine,Wuhan 430000,China

    TAO Junxiu,LI Xiaodong,Liver Disease branch,Hubei Provincial Hospital of Traditional Chinese Medicine,Affiliated Hospital of Hubei University of Chinese Medicine,Hubei Institute of Traditional Chinese Medicine,Wuhan 430000,China

    LI Li,CHEN Yun,LI Kejian,HE Jing,LIU Ru,GUO Juan,Psychology Department,Hubei Provincial Hospital of TCM,Affiliated Hospital of Hubei University of Chinese Medicine,Hubei Institute of Traditional Chinese Medicine,Wuhan 430000,China

    ZHANG Jia,ZHU Hui,Clinical College of Traditional Chinese Medicine,Hubei University of Traditional Chinese Medicine,Wuhan 430061,China

    Abstract OBJECTIVE: To evaluate the efficacy of the Shugan Jieyu capsule (舒肝解郁膠囊) on improving sleep and emotional disorder during Coronavirus disease 2019(COVID-19) convalescence.METHODS: We conducted a randomized,double-blind,placebo-controlled trial,and recruit 200 COVID-19 convalescence patients and then divide the subjects into two groups respectively: the experimental group (n= 100)and the control group (n= 100).Patients in the control group were given doses as a placebo,while those in the experimental group were given Shugan Jieyu capsule.The investigators mainly observed the differences between the two groups before and after treatment in terms of the rate of reduction and the rate of efficiency in Hamilton Depression Scale (HAMD-17) total scores from baseline,and recorded the scores of Hamilton Anxiety Scale (HAMA),Patient Health Questionnaire-15 (PHQ-15),Insomnia Severity Index (ISI) and Treatment Emergent Symptom Scale at 2 week,the 4 week and the 6 week respectively after treatment,and compared the differences between the groups.And the occurrence of adverse events was recorded.RESULTS: After 6-week treatment,there were statistically significant differences in the rate of reduction as well as efficiency in HAMD-17 scores,HAMA Total Scores,PHQ-15 Score,ISI Score from baseline in the experimental group and control group (P < 0.05).There were 4 adverse events in the experimental group and 1 in the control group.CONCLUSION: Shugan Jieyu capsule could significantly improve sleep and emotional disorder in patients during COVID-19 convalescence.

    Keywords: COVID-19;convalescence;sleep quality;emotional disorder;Shugan Jieyu capsule

    1.INTRODUCTION

    Coronavirus Disease 2019 (COVID-19),in the early stage,presents main symptoms of fatigue,fever,dry cough and so on,accompanied by gastrointestinal symptoms such as diarrhea,nausea,vomiting,and constipation.1,2During the convalescence,the patients can be cancelled out from isolation or can be discharged for COVID-19 convalescence when their body temperatures have been in a normal range for more than 3 d;their respiratory symptoms have been reduced significantly;their lung imaging has showed better absorption of inflammation;and the two consecutive nucleic acid tests of respiratory pathogens should be negative (the sampling intervals should be at least 1 d).

    However,given that the development of the pandemic subtly affects the physical and mental health of the public,some patients,even after entering COVID-19 convalescence,still have sleep disorders such as insomnia,or emotional disorders such as depression and anxiety,affecting their quality of life during COVID-19 convalescence.3

    For this part,sufficient attention should be paid to further improve the life quality of the discharged patients during COVID-19 convalescence and to speed up the recovery process.The importance of Traditional Chinese Medicine (TCM) in major infectious diseases has been emphasized in the whole-process intervention to patients with COVID-19 fromThe Diagnosis and Treatment Protocol for COVID-19 Patients.4Therefore,in this study,the investigators,having considered the abovementioned symptoms of patients during COVID-19 convalescence,select Shugan Jieyu capsule (舒肝解郁膠囊),a traditional Chinese patent medicine,as the intervention drug,and evaluate its effect on clinical symptoms such as insomnia,anxiety,and depression with a randomized,double-blind,placebo-controlled design,thus forming an effective clinical treatment protocol of TCM intervention during the COVID-19 convalescence.

    2.MATERIALS AND METHODS

    2.1.Study design

    A randomized, double-blind, placebo-controlled trial was conducted, with 200 patients during COVID-19 convalescence were recruited from July 2020 to September 2020, presenting clinical symptoms related to sleep and emotional disorders such as depression, anxiety, and insomnia.Totally 200 patients were randomly divided into experimental group (n= 100) and the control group (n= 100) on the basis of random number table method.The experimental group was treated with Shugan Jieyu capsule, while the control group was treated with placebo.The overall intervention course was 6 weeks, and the 0 week, the 2nd week, the 4th week as well as the 6th week respectively were taken as the observation nodes for the follow-up and health management.After the end of the treatment period, the clinical symptoms of the two groups continued to be observed.The protocol was approved by the Ethics Committee of Hubei Hospital of Traditional Chinese Medicine (HBZY2020-C27-01).This study was registered in Chinese Clinical Trial Registry (ChiCTR-2100043108).

    2.2.Inclusion criterias

    The research included the following patients: (a) those meeting the diagnostic criteria of COVID-19 convalescence;5(b) those aged between 18 and 70 years old, male or female; (c) those simultaneously having 2 symptoms of sleep and emotional disorder of depression, anxiety, poor sleeping quality, fatigue as the main clinical manifestations; (d) those scoring ≥ 17 and ≤ 24 of Hamilton Depression Scale (HAMD 17) total scores from baseline; (e) those scoring ≥ 5 of Patient Health Questionnaire-15 (PHQ-15); (f) those signing an informed consent form.

    2.3.Exclusion criterias

    Those patients would be excluded: (a) patients who have difficulties in oral medication due to underlying health conditions; (b) Patients with combination of serious primary diseases and dysfunctions of the heart, brain, respiratory, gastrointestinal, endocrine, hematopoietic, liver or kidney; (c) patients with schizophrenia, bipolar disorder, somatoform disorder, mania, anorexia, bulimia, or other types of mental illnesses, as well as histories of mental illnesses; (d) those who cannot cooperate due to their mental state, suffer from mental illnesses, and have difficulty in self-control; (e) those who have serious suicide intention(with HAMD-17 suicide scores ≥ 4) and intended to hurt others; (f) those who have allergies or are allergic to the drug involved in their treatment protocol; (g) pregnant women or women in lactation; (h) those who are participating in other clinical trials; (i) those patients whose participation and enrolment, in the judgement of the investigators, will affect the assessment of efficacy and safety negatively.

    2.4.Interventions

    The drug volume was allocated and obtained by the central randomization system.The intervention course lasted for 6 weeks, and the patients were not allowed to be given adjustments to their respective doses.The drug used in the research should be placed specifically with full-time pharmacists responsible for the storage and distribution.It was required that the drug must be in a place in consistence with the storage conditions under the specific personnel responsibility.The receipt and distribution of the drug must be clearly recorded with details, including the time, the drug volume, and the information of the receivers and the distributors of the drug and other necessary details.

    The experimental group: all the intervention drugs for all subjects were Shugan Jieyu capsule (Batch Number: S200501), with the drug specification: 0.36 g/capsule, 2 capsules once, twice a day per os.The control group: the subjects’ intervention drugs were Shugan Jieyu capsule placebo (Batch Number: S200501-1), with the drug specification: 0.36 g/capsule, 2 capsules once, twice a day per os.

    2.5.Outcomes

    2.5.1.Primary outcome

    The investigators compared differences between the two groups by calculating the rate of reduction and efficiency in HAMD-17 total scores from baseline after the 2nd week, the 4th week, and the6th week of the treatment.The rate of reduction (100%) = (total scores form baseline-total scores after treatment)/ total scores from baseline x 100%; the grading standards for obvious rate of efficiency are: for remission: HAMD total scores ≤ 7;for response rate: the total scores of HAMD reduced ≥ 50%, but the total scores> 7; for treatment inefficiency: the total scores of HAMD reduced < 50%; the obvious effective rate = (remission + response rate) / the number of people in each analysis set 100%.

    2.6.Secondary outcomes

    To record the scores of Hamilton Anxiety Scale (HAMA), PHQ-15, Insomnia Severity Index (ISI), and Treatment Emergent Symptom Scale after the 2nd week, the 4th week, and the 6th week of the treatment and then to compare the differences between groups.

    2.7.Safety outcomes

    The safety outcomes of the experimental group and the control group include the incidence of adverse events and serious adverse events, vital signs, physical examination, laboratory examination and electrocardiogram examination.

    2.8.Statistical analysis

    We applied the statistical analysis software SAS 9.4 (SAS Institute, Cary, NC, USA) for calculations.For the comparison between the groups, the investigators used a significant level of 0.05 for a two-sided test.P≤ 0.05 would be considered as statistically significant for the differences tested, and a 95% confidence shall be used in the credible interval.Continuous variables shall be summarized by descriptive statistics, including the number of cases, mean ± standard deviation.For measurement data (continuous variable-oriented test or Wilcoxon rank-sum test) shall be generally used.The investigators sum the descriptive statistics, including the number of subjects, percentages, and/or the number of events with categorical variables.If the number of cases is 0, then the percentage shall not be calculated.If no specification, the denominator for the percentage calculated shall be the total number of the subjects in the corresponding group where the analyzed subjects are included.The Cochran-Mantel-Haenszel test (CMH), c2test or Fisher's exact test shall be generally adopted in the comparison between the groups with categorical variables.

    3.RESULTS

    3.1.Baseline characteristics of the patients

    Experimental group (n =100) and the control group (n =100) was given 1 (1.0%) subject without taking drug after the randomization respectively.2 (2.0%) subjects in the placebo group lost to follow-up.Finally, the statistical analysis included 196 patients, as shown in Figure 1.

    Figure 1 Study design and flow chart

    The descriptive demography summary of this study is, as following (Table 1) with the patients’ age, body mass index (BMI) and gender, accompanied somatization symptoms, the time from onset to intervention evenly distributed.There is no statistical difference in the superiority trial between groups (P> 0.05), nor the usage of medication to improve emotion and reduce depression in the past 3 months.The summary results of the exposure and compliance of the drug shall be referred to in the table below (Table 1).The data of drug exposure and compliance of the subjects in this study are generally good.

    3.2.Depression symptoms--HAMD-17 score

    The results of changed in the 6th week of HAMD-17 total scores relative to the baseline with MMRM model analysis were as followed: from the comparison between the experimental group and control group (P< 0.001), the superiority trial between the groups was statistically significant, namely Shugan Jieyu capsule could significantly improve the patient's depressive symptoms with Table 2 for details.From the 2nd week, compared with the placebo group, the experimental group witnessed the decreased total scores of HAMD-17, while the linearly increased growth with follow-up examinations.

    3.3.Depressive symptoms—effective rate of HAMD-17 score

    The results of the obvious rate of efficiency in HAMD-17 scores are shown in Table 3 below.HAMD total scores ≤ 7; response rate: HAMD total scores reduction ≥ 50%, but total scores > 7; ineffective treatment: HAMD total scores reduction < 50%; the obvious rate of efficiency = (remission + response rate)/the number of people in the analysis set with the follow-up examinations in each group x 100%.The comparativePvalue between the groups in the 6th week is < 0.001, and the superiority test result is statistically significant.

    3.4.Anxiety symptoms—HAMA total scores

    The results of the changes of HAMA total scores from baseline in the 6th week analyzed by the MMRM model (P< 0.001), and the superiority test between the groups was statistically significant.It means, Shugan Jieyu capsule could significantly relieve the anxiety symptoms of patients, as shown in the Table 4 below.From the 2nd week, compared with the placebo group, the experimental group witnessed the faster decrease in total HAMA scores, while the linear growth with the increased follow-up examinations.

    3.5.Physical symptoms--PHQ-15 score

    The results of changes in the PHQ-15 score from baseline with the MMRM model in the 6th week showed that the comparisonP< 0.001, the superiority test between the two groups was statistically significant.That is, the Shugan Jieyu capsule could significantly relieve patients’ physical symptoms (Table 5).From the 2nd week, compared with the placebo group, the experimental group presented the faster decreased PHQ-15 total scores, while the linear growth with the increased follow-up examinations.

    Table 1 Baseline characters [n (%)]

    Table 2 Analysis on the 6-week changes in HAMD-17 total scores from baseline with MMRM model

    Table 3 Obvious rate of efficiency in HAMD-17 score on the 6th Week

    Table 4 Analysis on 6-week changes in HAMA total scores from baseline with MMRM model

    Table 5 Analysis on 6-week changes in PHQ-15 Score from baseline with MMRM model

    Table 6 Analysis on 6-week changes in ISI Score from baseline with MMRM model

    3.6.Sleep disorder symptoms-ISI score

    The results of changes of the ISI score from baseline in the 6th week analyzed by MMRM model (P< 0.001), and the superiority test between the groups was statistically significant.That is, Shugan Jieyu capsule could significantly relieve the symptoms of sleep disorders in patients (Table 6).From the 2nd week, compared with the placebo group, the experimental group showed a faster decrease in total ISI scores, while the linear growth with more follow-up examinations.

    3.7.Safety analysis

    Safety Set will be used as the primary population for the safety analysis in this study.The safety analysis includes adverse events, laboratory tests, vital signs, physical examinations and electrocardiograms.During the treatment period, the adverse events among the 4 subjects in the treatment period of Shugan Jieyu capsule group were mild diarrhea, Abnormal liver function, cervical polyp, and stomach pain” respectively.All these abovementioned events except for cervical polyp were adversereactions.One adverse event in the placebo group was mild gastrointestinal discomfort, which was not judged as an adverse reaction.The laboratory examinations, vital signs, physical examinations, and electrocardiograms of the two groups showed no change from baseline or abnormality without clinical significance turned to those with clinical significance.The overall safety results were good in both groups (Table 7).

    Table 7 Adverse events during treatment

    4.DISCUSSION

    As the sequelae are difficult to completely be eradicated after the patients’ virology turns negative when they enter COVID-19 convalescence.Bad emotions affect sleep disorders and aggravate the physical discomfort of the patients.A timely psychological adjustment will be conducive to the recovery of social order as well as the health of people's lives after the pandemic.

    After 6 weeks of treatment, the scores depression and anxiety level of the patients were significantly improved, and the accompanying physical symptoms and insomnia were also significantly relieved.As Liet al6found in the study of Shugan Jieyu capsule in the treatment of patients with rheumatoid arthritis and depression, the Shugan Jieyu capsule has the same effect as paroxetine, which can reduce the depression and anxiety level of patients.Although western medicine can improve depression to some extent, they also have many adverse reactions or side effects, such as gastrointestinal reactions, dizziness, drowsiness, weight gain and so on.7It is suggested that given the curative effect is quite the same, TCM can be used in combination to better the curative effect.During the observation period of the curative effect of Shugan Jieyu capsule in the treatment of perimenopausal women with insomnia, we found that the symptoms of perimenopausal women, such as hot flashes, sweating, irritability and insomnia, can be well improved, as well as reducing the adverse drug reactions and relieving drug dependence concerns.

    In this study, the Shugan Jieyu capsule is mainly composed of Guanyelianqiao (Herba Hyperici Perforati, GYLQ) and Ciwujia (Radix et Caulis Acanthopanacis Santicosi) (CWJ).GYJST is relatively cold constitution in nature and pungent in taste.It contributes to the liver.It has the effects of soothing the liver and reducing depression, helping calm down, reducing swelling and promoting lactation.CWJ is pungent, slightly bitter, heat constitution in nature, contributing to the spleen, kidney and heart.It has the functions of invigoratingQi, strengthening kidney and making people calm and sedative.Given these functions, it can be used for patients with spleen-kidney deficiency, physical weakness, loss of appetite, sores or pains in the waist and knee, insomnia and dreaminess.Modern studies have shown that GYLQ can activate central nervous systems, increase the concentration of neurotransmitters in the synaptic cleft, decrease the density of adrenergic receptors in the presynaptic membrane, regulate the thalamus-pituitary-adrenal axis, and help antidepression.8CWJ contains non-aromatic unsaturated organic acids and a variety of trace minerals.It has sedative and anti-fatigue effects which can help establish normal sleep cycles, and have greater advantages in the treatment of sleep disorders.The treatment effect is the same as that of the western medicine Fluoxetine, but with fewer adverse drug reactions and more safety.

    The outbreak of the pandemic not only deprives us of lives and property, but also causes severe psychological trauma to humanity.With the extreme infection conditions, most COVID-19 related patients need longterm isolation treatment.Negative emotions are thus easily generated to a certain degree as they suddenly have to cut their connections to the outside world, facing physical burdens independently in relatively isolated space.9The treatment of COVID-19 should not only focus on physical diseases, but also psychological intervention.“Body mind” is an important principle in the holistic view of TCM to improving liver and spleen.Applying Shugan Jieyu capsule will promptly intervene psychological stress accumulated in the context of the pandemic.10,11

    There may be some limitations in this study.COVID-19 is a newly emerging infectious disease in the world, and there is no data from previous studies and no therapeutic effect value of intervention measures for reference.Meanwhile, the sample size estimated lacks data support from previous studies, the source of sample is limited and the size of sample is relatively small.Shugan Jieyu capsule has shown obvious curative effect since 2 weeks, but according to the characteristics and treatment scheme of depression, it can avoid the recurrence and resurgence of symptoms because it is taken persistently.12Considering the special background of the disease at that time and referring to the previous data of Shugan Jieyu capsule, the research scheme of this project is only designed for the treatment period of 6 weeks, so the follow-up after drug withdrawal is not carried out.In order to ensure the scientific accuracy of this study as much as possible,the opinions of statistical experts were used as the main reference for sample size consideration,and strict quality control was carried out on the research process and results,including strengthening the training of investigators,checking the integrity,logic and extreme values of data,and using various statistical methods to control the possible deviation as little as possible.

    In conclusion,the findings showed that the potential effect of Shugan Jieyu capsule on COVID-19 convalescence patients with depression,anxiety and insomnia suggests the role of TCM in mental health of COVID-19 patients during convalescence.13The positive effect should be further investigated in trials with a greater number of patient groups and longer follow-up duration.

    猜你喜歡
    膠囊
    Shumian capsule(舒眠膠囊)improves symptoms of sleep mood disorder in convalescent patients of Corona Virus Disease 2019
    時光膠囊
    聊聊疏風解毒膠囊
    腰痛寧膠囊使用心得
    時光膠囊
    益肺止咳膠囊的顯微鑒別研究
    中成藥(2018年12期)2018-12-29 12:26:08
    HPLC法同時測定醒黛膠囊中3種成分
    中成藥(2018年9期)2018-10-09 07:19:02
    地龍降壓膠囊對SHR大鼠早期腎損害的保護作用
    中成藥(2018年8期)2018-08-29 01:28:22
    HPLC法同時測定消結(jié)安膠囊中4種成分
    中成藥(2017年3期)2017-05-17 06:08:59
    脈血康膠囊治療老年恢復(fù)期腦梗死30例
    精品人妻偷拍中文字幕| 男人舔奶头视频| 精品久久久噜噜| 午夜精品国产一区二区电影 | 亚洲国产成人一精品久久久| 日韩一区二区视频免费看| 亚洲av二区三区四区| 亚洲av国产av综合av卡| 高清av免费在线| 国产免费一区二区三区四区乱码| 如何舔出高潮| 欧美激情国产日韩精品一区| 蜜臀久久99精品久久宅男| 国产av不卡久久| 亚洲综合精品二区| 99热这里只有是精品50| 国产熟女欧美一区二区| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 国产爽快片一区二区三区| 色5月婷婷丁香| 肉色欧美久久久久久久蜜桃 | 成人美女网站在线观看视频| 麻豆久久精品国产亚洲av| 日产精品乱码卡一卡2卡三| 高清av免费在线| 99久久精品国产国产毛片| 亚洲久久久久久中文字幕| 欧美+日韩+精品| 亚洲精品视频女| 国产成人精品婷婷| 精品一区二区三区视频在线| 国产日韩欧美在线精品| 亚洲av欧美aⅴ国产| 啦啦啦在线观看免费高清www| 听说在线观看完整版免费高清| 国产精品一区www在线观看| 中文字幕人妻熟人妻熟丝袜美| 亚洲最大成人中文| 亚洲欧洲国产日韩| 欧美xxxx黑人xx丫x性爽| 女的被弄到高潮叫床怎么办| 色综合色国产| 精品久久久久久久久亚洲| a级毛片免费高清观看在线播放| 麻豆成人午夜福利视频| 国产伦精品一区二区三区四那| 欧美xxⅹ黑人| 亚洲国产欧美人成| 在线免费观看不下载黄p国产| 亚洲丝袜综合中文字幕| 午夜日本视频在线| 丰满乱子伦码专区| 韩国高清视频一区二区三区| 欧美人与善性xxx| 国产极品天堂在线| 欧美性感艳星| 亚洲国产成人一精品久久久| 色网站视频免费| 国产精品秋霞免费鲁丝片| 免费观看无遮挡的男女| 涩涩av久久男人的天堂| 亚洲电影在线观看av| 国产成人免费观看mmmm| 国产老妇伦熟女老妇高清| 丝袜喷水一区| 22中文网久久字幕| 久久人人爽av亚洲精品天堂 | 亚洲丝袜综合中文字幕| 精品人妻偷拍中文字幕| 青青草视频在线视频观看| 人妻系列 视频| 国产午夜精品一二区理论片| 国产一区二区三区av在线| 日本av手机在线免费观看| 啦啦啦啦在线视频资源| 成年版毛片免费区| 99久久精品热视频| 国产精品熟女久久久久浪| 黄色欧美视频在线观看| 亚洲精品自拍成人| 在线观看美女被高潮喷水网站| 韩国高清视频一区二区三区| 亚洲色图av天堂| 搡女人真爽免费视频火全软件| 91久久精品国产一区二区成人| 中文字幕制服av| www.av在线官网国产| 欧美bdsm另类| 一区二区三区乱码不卡18| 极品少妇高潮喷水抽搐| 天堂中文最新版在线下载 | 亚洲精品一区蜜桃| 亚洲欧美一区二区三区黑人 | 免费av毛片视频| 午夜老司机福利剧场| 久久精品国产鲁丝片午夜精品| 亚洲成人av在线免费| 亚洲av.av天堂| 久久久久九九精品影院| 日韩电影二区| 亚洲av中文av极速乱| 精品一区在线观看国产| 国产乱来视频区| 国产伦在线观看视频一区| 欧美日韩在线观看h| 天美传媒精品一区二区| 伊人久久国产一区二区| 国内少妇人妻偷人精品xxx网站| 成人特级av手机在线观看| 国产精品国产三级国产专区5o| 日韩成人伦理影院| 美女主播在线视频| 禁无遮挡网站| 久久久欧美国产精品| 免费高清在线观看视频在线观看| 国产成人a∨麻豆精品| 亚洲av在线观看美女高潮| 色网站视频免费| 国产欧美另类精品又又久久亚洲欧美| 免费在线观看成人毛片| 人人妻人人爽人人添夜夜欢视频 | 99久久九九国产精品国产免费| 国产一区二区在线观看日韩| 日本欧美国产在线视频| 人妻一区二区av| 哪个播放器可以免费观看大片| 女人十人毛片免费观看3o分钟| 免费黄网站久久成人精品| 色网站视频免费| 国产欧美另类精品又又久久亚洲欧美| 成年免费大片在线观看| 美女脱内裤让男人舔精品视频| 五月玫瑰六月丁香| 国产精品99久久99久久久不卡 | 一区二区三区免费毛片| 日韩欧美一区视频在线观看 | 1000部很黄的大片| av在线天堂中文字幕| 晚上一个人看的免费电影| h日本视频在线播放| 免费不卡的大黄色大毛片视频在线观看| 麻豆成人午夜福利视频| 免费大片黄手机在线观看| 亚洲怡红院男人天堂| 禁无遮挡网站| 久久久久久久久久成人| 日本wwww免费看| 大香蕉97超碰在线| 欧美人与善性xxx| 成人国产麻豆网| 精品久久久久久久久av| a级毛色黄片| 午夜视频国产福利| 永久免费av网站大全| av一本久久久久| 蜜桃亚洲精品一区二区三区| 国产精品久久久久久久电影| 有码 亚洲区| a级毛色黄片| 成人免费观看视频高清| 亚洲伊人久久精品综合| 欧美xxxx性猛交bbbb| 在线精品无人区一区二区三 | 精品久久久精品久久久| 国产精品国产av在线观看| 97人妻精品一区二区三区麻豆| 好男人视频免费观看在线| 国产欧美日韩一区二区三区在线 | 99久久精品国产国产毛片| 看黄色毛片网站| 日本午夜av视频| 丰满少妇做爰视频| 日韩欧美一区视频在线观看 | 日韩人妻高清精品专区| 久久韩国三级中文字幕| 欧美潮喷喷水| 精品国产乱码久久久久久小说| 成人无遮挡网站| 男女那种视频在线观看| 亚洲精品视频女| 国产av国产精品国产| av在线老鸭窝| 欧美日韩精品成人综合77777| av国产久精品久网站免费入址| 国产色婷婷99| 亚洲自拍偷在线| 好男人视频免费观看在线| 久久精品熟女亚洲av麻豆精品| 日产精品乱码卡一卡2卡三| 亚洲国产精品成人综合色| tube8黄色片| 午夜日本视频在线| 亚洲婷婷狠狠爱综合网| 91精品一卡2卡3卡4卡| av国产免费在线观看| 国产成人a∨麻豆精品| 亚洲三级黄色毛片| 免费播放大片免费观看视频在线观看| 国产黄色视频一区二区在线观看| 亚洲av二区三区四区| 国产亚洲91精品色在线| 中文字幕免费在线视频6| 日本-黄色视频高清免费观看| 亚州av有码| 狂野欧美白嫩少妇大欣赏| 搞女人的毛片| 国产欧美另类精品又又久久亚洲欧美| 18禁动态无遮挡网站| 成年女人看的毛片在线观看| 69人妻影院| 国产色爽女视频免费观看| 日韩av在线免费看完整版不卡| 日韩成人av中文字幕在线观看| 国产91av在线免费观看| 国产黄色免费在线视频| 国内精品宾馆在线| 亚洲欧美日韩东京热| 99热网站在线观看| 亚洲成人一二三区av| 人体艺术视频欧美日本| 嫩草影院新地址| 亚洲在线观看片| 亚洲欧美精品专区久久| 国内精品宾馆在线| 不卡视频在线观看欧美| 欧美精品国产亚洲| 中文字幕亚洲精品专区| 男人舔奶头视频| 91久久精品国产一区二区成人| 一级毛片aaaaaa免费看小| av免费观看日本| 成年人午夜在线观看视频| 国产成人freesex在线| 97超视频在线观看视频| 特大巨黑吊av在线直播| 午夜日本视频在线| 老司机影院成人| 欧美激情国产日韩精品一区| 一级毛片电影观看| 成人美女网站在线观看视频| 草草在线视频免费看| 少妇人妻精品综合一区二区| 午夜福利在线观看免费完整高清在| 免费大片18禁| 精品视频人人做人人爽| 免费av毛片视频| 青春草国产在线视频| 人体艺术视频欧美日本| 国产综合精华液| 免费少妇av软件| eeuss影院久久| 在线免费十八禁| 国产白丝娇喘喷水9色精品| 一级a做视频免费观看| 国产91av在线免费观看| 黄片无遮挡物在线观看| 亚洲欧美一区二区三区国产| 欧美区成人在线视频| 99九九线精品视频在线观看视频| 国产探花在线观看一区二区| 一级毛片 在线播放| 韩国高清视频一区二区三区| 22中文网久久字幕| 国产精品熟女久久久久浪| 国产探花极品一区二区| 久久久精品欧美日韩精品| 涩涩av久久男人的天堂| 亚洲精品日韩av片在线观看| 国产中年淑女户外野战色| 国产老妇女一区| 嫩草影院精品99| 尤物成人国产欧美一区二区三区| 五月伊人婷婷丁香| 欧美丝袜亚洲另类| 大话2 男鬼变身卡| 丰满少妇做爰视频| 国产成人freesex在线| 国产一区二区亚洲精品在线观看| 国产一区有黄有色的免费视频| 国产一区二区三区av在线| 亚洲国产色片| 两个人的视频大全免费| 亚洲欧美清纯卡通| 五月开心婷婷网| 在线观看国产h片| 男人添女人高潮全过程视频| 一本色道久久久久久精品综合| 极品教师在线视频| 亚洲欧美精品专区久久| 久久人人爽人人片av| 人妻夜夜爽99麻豆av| 亚洲婷婷狠狠爱综合网| 国产欧美日韩精品一区二区| 一本色道久久久久久精品综合| 女的被弄到高潮叫床怎么办| 五月伊人婷婷丁香| 极品教师在线视频| 五月伊人婷婷丁香| 特大巨黑吊av在线直播| 日本午夜av视频| 韩国高清视频一区二区三区| 自拍偷自拍亚洲精品老妇| 中文乱码字字幕精品一区二区三区| 欧美日韩综合久久久久久| 国产高清有码在线观看视频| 日本熟妇午夜| 69人妻影院| 91狼人影院| 各种免费的搞黄视频| 熟妇人妻不卡中文字幕| 久久精品国产自在天天线| 超碰97精品在线观看| 久久久亚洲精品成人影院| 国产在视频线精品| 精品熟女少妇av免费看| 免费观看无遮挡的男女| 亚洲欧美日韩东京热| 成人漫画全彩无遮挡| 久久这里有精品视频免费| 七月丁香在线播放| 国产色爽女视频免费观看| 日韩精品有码人妻一区| 晚上一个人看的免费电影| 人人妻人人爽人人添夜夜欢视频 | 人体艺术视频欧美日本| av国产久精品久网站免费入址| 五月开心婷婷网| 久久99热这里只频精品6学生| 中文资源天堂在线| 一级二级三级毛片免费看| 成人午夜精彩视频在线观看| 一边亲一边摸免费视频| 亚洲三级黄色毛片| 久久久国产一区二区| 亚洲av成人精品一区久久| 久久久久久伊人网av| 99热这里只有精品一区| 亚洲欧洲国产日韩| 国产乱人偷精品视频| 少妇人妻 视频| 国产精品蜜桃在线观看| 91aial.com中文字幕在线观看| 乱系列少妇在线播放| 日本黄大片高清| 久久久久九九精品影院| 国产高清不卡午夜福利| 能在线免费看毛片的网站| 色综合色国产| 91精品伊人久久大香线蕉| www.av在线官网国产| av在线播放精品| 伊人久久精品亚洲午夜| 欧美激情在线99| 欧美激情久久久久久爽电影| 亚洲色图综合在线观看| 久久久久国产网址| 亚洲,一卡二卡三卡| 精品少妇黑人巨大在线播放| 免费观看无遮挡的男女| 老司机影院毛片| 免费观看无遮挡的男女| 老司机影院毛片| 毛片一级片免费看久久久久| 日韩国内少妇激情av| 国产高清国产精品国产三级 | 纵有疾风起免费观看全集完整版| av女优亚洲男人天堂| 交换朋友夫妻互换小说| 亚洲精品成人av观看孕妇| 大话2 男鬼变身卡| 99久久精品国产国产毛片| 亚洲第一区二区三区不卡| 国产在视频线精品| 亚洲成色77777| 激情五月婷婷亚洲| 在线观看一区二区三区激情| 久久人人爽人人爽人人片va| 可以在线观看毛片的网站| 亚洲国产精品专区欧美| 新久久久久国产一级毛片| 成人亚洲精品一区在线观看 | 深爱激情五月婷婷| 国产日韩欧美在线精品| 亚洲国产欧美人成| 国产又色又爽无遮挡免| 亚洲欧洲国产日韩| videos熟女内射| 亚洲精品久久久久久婷婷小说| 三级国产精品片| 在线看a的网站| 简卡轻食公司| 男人舔奶头视频| 亚洲最大成人手机在线| 国产乱人视频| 日韩成人av中文字幕在线观看| 亚洲最大成人中文| av又黄又爽大尺度在线免费看| 欧美97在线视频| 九色成人免费人妻av| 女的被弄到高潮叫床怎么办| 精品久久久久久电影网| 国产一级毛片在线| 精品一区二区免费观看| 免费黄频网站在线观看国产| 国产伦精品一区二区三区视频9| 又爽又黄a免费视频| 一级毛片aaaaaa免费看小| 我的女老师完整版在线观看| 99热这里只有是精品50| 日韩不卡一区二区三区视频在线| videos熟女内射| 久久这里有精品视频免费| 亚洲最大成人av| 波多野结衣巨乳人妻| 精品午夜福利在线看| 亚洲三级黄色毛片| 我的女老师完整版在线观看| av专区在线播放| 免费播放大片免费观看视频在线观看| 老女人水多毛片| 久久久国产一区二区| 乱码一卡2卡4卡精品| 亚洲av免费在线观看| 在线免费十八禁| 国产精品国产三级专区第一集| 免费看av在线观看网站| 精品人妻偷拍中文字幕| 亚洲成人一二三区av| 精品久久久久久久久亚洲| 热re99久久精品国产66热6| av国产免费在线观看| 欧美xxxx性猛交bbbb| 黄片无遮挡物在线观看| 99热这里只有精品一区| eeuss影院久久| 又爽又黄a免费视频| 久久精品久久久久久噜噜老黄| 涩涩av久久男人的天堂| 国产亚洲5aaaaa淫片| 久久精品久久久久久久性| 日韩伦理黄色片| 欧美3d第一页| 亚洲av成人精品一二三区| 少妇熟女欧美另类| 久久精品久久久久久噜噜老黄| 涩涩av久久男人的天堂| 亚洲av男天堂| 国产伦精品一区二区三区四那| 偷拍熟女少妇极品色| 国产在线男女| 久久6这里有精品| 亚洲精品一二三| 免费观看无遮挡的男女| 插逼视频在线观看| 亚洲国产最新在线播放| 男的添女的下面高潮视频| 美女高潮的动态| 久久久亚洲精品成人影院| 婷婷色av中文字幕| 3wmmmm亚洲av在线观看| 午夜精品国产一区二区电影 | av女优亚洲男人天堂| 亚洲精品视频女| 日韩强制内射视频| 九草在线视频观看| 99久国产av精品国产电影| 国产老妇女一区| 人妻少妇偷人精品九色| 自拍偷自拍亚洲精品老妇| 伦精品一区二区三区| 国产免费一级a男人的天堂| videossex国产| 亚洲精品aⅴ在线观看| 国模一区二区三区四区视频| 久久久亚洲精品成人影院| 啦啦啦啦在线视频资源| 91aial.com中文字幕在线观看| 久久久久久久久久久丰满| 欧美日韩视频精品一区| 婷婷色av中文字幕| 日韩中字成人| 国产美女午夜福利| 只有这里有精品99| 国产69精品久久久久777片| 国产永久视频网站| 亚洲图色成人| 午夜激情久久久久久久| 亚洲三级黄色毛片| 日本爱情动作片www.在线观看| 在线天堂最新版资源| 熟女人妻精品中文字幕| 亚洲精品乱码久久久久久按摩| 亚洲国产成人一精品久久久| 免费av毛片视频| 高清在线视频一区二区三区| 精品久久国产蜜桃| 一个人看视频在线观看www免费| 亚洲av电影在线观看一区二区三区 | 国产精品蜜桃在线观看| 亚洲美女视频黄频| 观看免费一级毛片| 亚洲av电影在线观看一区二区三区 | 白带黄色成豆腐渣| 亚洲,一卡二卡三卡| 日本黄大片高清| 热re99久久精品国产66热6| 91aial.com中文字幕在线观看| 国产日韩欧美亚洲二区| 欧美国产精品一级二级三级 | 下体分泌物呈黄色| 国产真实伦视频高清在线观看| 中文乱码字字幕精品一区二区三区| 国产一区二区三区av在线| 久久久a久久爽久久v久久| 久久久成人免费电影| 人妻 亚洲 视频| 少妇猛男粗大的猛烈进出视频 | 午夜福利视频1000在线观看| 亚洲精品,欧美精品| 国产美女午夜福利| 日本wwww免费看| 成人欧美大片| 成人特级av手机在线观看| 三级经典国产精品| 午夜亚洲福利在线播放| www.av在线官网国产| 毛片女人毛片| 纵有疾风起免费观看全集完整版| 亚洲国产成人一精品久久久| 亚洲内射少妇av| 国产午夜精品一二区理论片| 一区二区三区免费毛片| 午夜福利在线在线| 天堂俺去俺来也www色官网| 日日撸夜夜添| 国产精品不卡视频一区二区| 美女xxoo啪啪120秒动态图| 一个人看的www免费观看视频| 国产精品一区www在线观看| 亚洲一区二区三区欧美精品 | 又黄又爽又刺激的免费视频.| 国产亚洲午夜精品一区二区久久 | 一级a做视频免费观看| 成人高潮视频无遮挡免费网站| 六月丁香七月| 成人亚洲精品一区在线观看 | 国产精品人妻久久久久久| 欧美成人a在线观看| 婷婷色麻豆天堂久久| 国产视频内射| 国产精品人妻久久久影院| 久久久a久久爽久久v久久| 少妇裸体淫交视频免费看高清| 欧美三级亚洲精品| 国产片特级美女逼逼视频| 欧美日韩精品成人综合77777| 精品久久久噜噜| 午夜激情久久久久久久| 成人免费观看视频高清| 一级黄片播放器| 两个人的视频大全免费| 内地一区二区视频在线| a级毛片免费高清观看在线播放| 中国美白少妇内射xxxbb| 久久久久久久午夜电影| 亚洲精华国产精华液的使用体验| 成人无遮挡网站| 亚洲欧美精品专区久久| 狂野欧美白嫩少妇大欣赏| 日日撸夜夜添| 十八禁网站网址无遮挡 | 99热6这里只有精品| 欧美日韩视频精品一区| 免费在线观看成人毛片| 日韩伦理黄色片| 建设人人有责人人尽责人人享有的 | 午夜老司机福利剧场| 女人久久www免费人成看片| a级毛片免费高清观看在线播放| 亚洲人成网站高清观看| 久久精品久久久久久噜噜老黄| 久久99热6这里只有精品| 亚洲精品乱码久久久久久按摩| 亚洲国产色片| 大话2 男鬼变身卡| 日韩欧美精品免费久久| 国产午夜福利久久久久久| 亚洲精品日本国产第一区| 99视频精品全部免费 在线| 亚洲精品日本国产第一区| 九九在线视频观看精品| 男人爽女人下面视频在线观看| 午夜视频国产福利| 69人妻影院| 欧美日韩综合久久久久久| 嫩草影院入口| 成年女人看的毛片在线观看| 亚洲精品影视一区二区三区av| 麻豆久久精品国产亚洲av| 人妻系列 视频| 久久精品久久久久久噜噜老黄| 中文在线观看免费www的网站| 日韩精品有码人妻一区| 免费人成在线观看视频色| 青青草视频在线视频观看| 亚洲性久久影院| 亚洲婷婷狠狠爱综合网| 成人毛片60女人毛片免费| 国产精品熟女久久久久浪| 婷婷色麻豆天堂久久| 三级国产精品片| 免费av毛片视频| 久热这里只有精品99| 国产男女内射视频| 久久久久久久久久成人|